Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Satoshi, Hirata, Kenji, Magota, Keiichi, Watanabe, Shiro, Moku, Rika, Shiiya, Akihiko, Taguchi, Jun, Ariga, Shin, Goda, Tomohiro, Ohhara, Yoshihito, Noguchi, Takurou, Shimizu, Yasushi, Kinoshita, Ichiro, Honma, Rio, Tsuji, Yasushi, Homma, Akihiro, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352209/
https://www.ncbi.nlm.nih.gov/pubmed/37460834
http://dx.doi.org/10.1186/s13550-023-01019-9
_version_ 1785074464336117760
author Takeuchi, Satoshi
Hirata, Kenji
Magota, Keiichi
Watanabe, Shiro
Moku, Rika
Shiiya, Akihiko
Taguchi, Jun
Ariga, Shin
Goda, Tomohiro
Ohhara, Yoshihito
Noguchi, Takurou
Shimizu, Yasushi
Kinoshita, Ichiro
Honma, Rio
Tsuji, Yasushi
Homma, Akihiro
Dosaka-Akita, Hirotoshi
author_facet Takeuchi, Satoshi
Hirata, Kenji
Magota, Keiichi
Watanabe, Shiro
Moku, Rika
Shiiya, Akihiko
Taguchi, Jun
Ariga, Shin
Goda, Tomohiro
Ohhara, Yoshihito
Noguchi, Takurou
Shimizu, Yasushi
Kinoshita, Ichiro
Honma, Rio
Tsuji, Yasushi
Homma, Akihiro
Dosaka-Akita, Hirotoshi
author_sort Takeuchi, Satoshi
collection PubMed
description BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes. RESULTS: This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion. Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation. Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation. The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT. Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve. Twenty-one patients were included in this analysis. Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment. The best cut-off value for the treatment response for SUVmax was 15.211. The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively. The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value (P = 0.078). CONCLUSIONS: The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT. PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC. Trial registration: This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016.
format Online
Article
Text
id pubmed-10352209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103522092023-07-19 Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study Takeuchi, Satoshi Hirata, Kenji Magota, Keiichi Watanabe, Shiro Moku, Rika Shiiya, Akihiko Taguchi, Jun Ariga, Shin Goda, Tomohiro Ohhara, Yoshihito Noguchi, Takurou Shimizu, Yasushi Kinoshita, Ichiro Honma, Rio Tsuji, Yasushi Homma, Akihiro Dosaka-Akita, Hirotoshi EJNMMI Res Original Research BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes. RESULTS: This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion. Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation. Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation. The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT. Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve. Twenty-one patients were included in this analysis. Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment. The best cut-off value for the treatment response for SUVmax was 15.211. The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively. The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value (P = 0.078). CONCLUSIONS: The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT. PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC. Trial registration: This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016. Springer Berlin Heidelberg 2023-07-17 /pmc/articles/PMC10352209/ /pubmed/37460834 http://dx.doi.org/10.1186/s13550-023-01019-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Takeuchi, Satoshi
Hirata, Kenji
Magota, Keiichi
Watanabe, Shiro
Moku, Rika
Shiiya, Akihiko
Taguchi, Jun
Ariga, Shin
Goda, Tomohiro
Ohhara, Yoshihito
Noguchi, Takurou
Shimizu, Yasushi
Kinoshita, Ichiro
Honma, Rio
Tsuji, Yasushi
Homma, Akihiro
Dosaka-Akita, Hirotoshi
Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title_full Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title_fullStr Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title_full_unstemmed Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title_short Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
title_sort early prediction of treatment outcome for lenvatinib using (18)f-fdg pet/ct in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352209/
https://www.ncbi.nlm.nih.gov/pubmed/37460834
http://dx.doi.org/10.1186/s13550-023-01019-9
work_keys_str_mv AT takeuchisatoshi earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT hiratakenji earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT magotakeiichi earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT watanabeshiro earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT mokurika earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT shiiyaakihiko earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT taguchijun earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT arigashin earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT godatomohiro earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT ohharayoshihito earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT noguchitakurou earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT shimizuyasushi earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT kinoshitaichiro earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT honmario earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT tsujiyasushi earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT hommaakihiro earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy
AT dosakaakitahirotoshi earlypredictionoftreatmentoutcomeforlenvatinibusing18ffdgpetctinpatientswithunresectableoradvancedthyroidcarcinomarefractorytoradioiodinetreatmentaprospectivemulticentrenonrandomisedstudy